Exact Mass: 357.19399820000007

Exact Mass Matches: 357.19399820000007

Found 31 metabolites which its exact mass value is equals to given mass value 357.19399820000007, within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error 0.0002 dalton.

(S)-Laudanosine

1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline

C21H27NO4 (357.19399820000007)


(S)-Laudanosine is found in opium poppy. (S)-Laudanosine is an alkaloid from Papaver somniferum (opium poppy Alkaloid from Papaver somniferum (opium poppy). (S)-Laudanosine is found in opium poppy. D002491 - Central Nervous System Agents DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity[1]. DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity[1].

   

Nalbuphine

(1S,5R,13R,14S,17S)-4-(cyclobutylmethyl)-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7,9,11(18)-triene-10,14,17-triol

C21H27NO4 (357.19399820000007)


Nalbuphine is only found in individuals that have used or taken this drug. It is a narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. [PubChem]The exact mechanism of action is unknown, but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system). The opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but may also be a result of other mechanisms. Nalbuphine is thought primarily to be a kappa agonist. It is also a partial mu antagonist analgesic, with some binding to the delta receptor and minimal agonist activity at the sigma receptor. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AF - Morphinan derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

   

5-hydroxypropafenone

1-{5-hydroxy-2-[2-hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one

C21H27NO4 (357.19399820000007)


5-hydroxypropafenone is a metabolite of propafenone. Propafenone is a class of anti-arrhythmic medication, which treats illnesses associated with rapid heart beats such as atrial and ventricular arrhythmias. (Wikipedia) D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents

   

(E)-(4-Acetoxycinnamoyl)-epilupinine

(E)-(4-Acetoxycinnamoyl)-epilupinine

C21H27NO4 (357.19399820000007)


   
   

methyl 4-((E)-2-acetyl-4-oxonon-1-enyl)-6-((E)-prop-1-enyl)nicotinate|monascopyridine E|Monasnicotinate A

methyl 4-((E)-2-acetyl-4-oxonon-1-enyl)-6-((E)-prop-1-enyl)nicotinate|monascopyridine E|Monasnicotinate A

C21H27NO4 (357.19399820000007)


   
   
   

Laudanosine

DL-LAUDANOSINE

C21H27NO4 (357.19399820000007)


D002491 - Central Nervous System Agents Annotation level-1 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.628 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.624 Acquisition and generation of the data is financially supported by the Max-Planck-Society IPB_RECORD: 2441; CONFIDENCE confident structure DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity[1]. DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity[1].

   

nalbuphine

nalbuphine

C21H27NO4 (357.19399820000007)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AF - Morphinan derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

   

5-hydroxypropafenone

5-hydroxypropafenone

C21H27NO4 (357.19399820000007)


D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents

   

Laudanoside

Laudanoside

C21H27NO4 (357.19399820000007)


Origin: Plant; Formula(Parent): C21H27NO4; Bottle Name:Laudanosine; PRIME Parent Name:Laudanosine; PRIME in-house No.:V0357; SubCategory_DNP: Isoquinoline alkaloids, Morphine alkaloids

   

butyl prop-2-enoate,prop-2-enenitrile,prop-2-enoic acid,styrene

butyl prop-2-enoate,prop-2-enenitrile,prop-2-enoic acid,styrene

C21H27NO4 (357.19399820000007)


   
   
   

(R)-laudanosine

(R)-laudanosine

C21H27NO4 (357.19399820000007)


A benzylisoquinoline alkaloid that is (R)-tetrahydropapaverine in which the amino hydrogen has been replaced by a methyl group

   

N-[[(1R,2R)-3-Oxo-2-[(Z)-2-pentenyl]cyclopentan-1-yl]acetyl]-L-phenylalanine

N-[[(1R,2R)-3-Oxo-2-[(Z)-2-pentenyl]cyclopentan-1-yl]acetyl]-L-phenylalanine

C21H27NO4 (357.19399820000007)


   

N-[[(1R)-3-Oxo-2alpha-[(Z)-2-pentenyl]cyclopentane-1alpha-yl]acetyl]-L-phenylalanine

N-[[(1R)-3-Oxo-2alpha-[(Z)-2-pentenyl]cyclopentane-1alpha-yl]acetyl]-L-phenylalanine

C21H27NO4 (357.19399820000007)


   

(2S)-2-[[2-[3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetyl]amino]-3-phenylpropanoic acid

(2S)-2-[[2-[3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetyl]amino]-3-phenylpropanoic acid

C21H27NO4 (357.19399820000007)


   

(4R,4aS,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol

(4R,4aS,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol

C21H27NO4 (357.19399820000007)


   

(4R,4aS,7S,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol

(4R,4aS,7S,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol

C21H27NO4 (357.19399820000007)


   

(S)-Laudanosine

(S)-Laudanosine

C21H27NO4 (357.19399820000007)


D002491 - Central Nervous System Agents

   
   
   

(1r,3r,4s,5s,8r,9s,11s,14s,17s,18r)-3,4-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-dione

(1r,3r,4s,5s,8r,9s,11s,14s,17s,18r)-3,4-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-dione

C21H27NO4 (357.19399820000007)


   

dimethyl(2-{4,13,14-trimethoxy-2-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-7-yl}ethyl)amine

dimethyl(2-{4,13,14-trimethoxy-2-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-7-yl}ethyl)amine

C21H27NO4 (357.19399820000007)


   

(1r)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinoline

(1r)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinoline

C21H27NO4 (357.19399820000007)


   

5-hydroxy-4-(1-hydroxy-2,4-dimethyloct-6-en-1-ylidene)-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

5-hydroxy-4-(1-hydroxy-2,4-dimethyloct-6-en-1-ylidene)-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

C21H27NO4 (357.19399820000007)


   

(4e)-5-hydroxy-4-[(6e)-1-hydroxy-2,4-dimethyloct-6-en-1-ylidene]-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

(4e)-5-hydroxy-4-[(6e)-1-hydroxy-2,4-dimethyloct-6-en-1-ylidene]-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

C21H27NO4 (357.19399820000007)